Literature DB >> 9243207

Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors.

A Imai1, S Horibe, A Takagi, T Ohno, T Tamaya.   

Abstract

OBJECTIVE: Fas, a cell surface receptor, mediates cell death by means of apoptosis in a variety of cell types. Gonadotropin-releasing hormone (GnRH) receptor-bearing tumors undergo the apoptosis with GnRH analogs. The authors attempted to determine the frequency with which Fas is present in the GnRH receptor-bearing tumors. STUDY
DESIGN: Surgically removed gynecological tumors were screened for GnRH receptor expression prior to analyses. Fas was characterized by immunoblotting of membrane proteins with the specific antibodies. Fas messenger ribonucleic acid (mRNA) was determined by reverse transcription-polymerase chain reaction using oligonucleotide primers synthesized according to the published Fas sequence.
RESULTS: Immunoreactive Fas and Fas mRNA were detected in a high proportion (94.4%) of the specimens from endometrial carcinomas (8 of 9), ovarian carcinomas (7 of 7), and uterine leiomyosarcomas (2 of 2); all these expressed GnRH receptor. There was neither substantial Fas nor GnRH receptor in 9 cervical carcinomas. Cloned cell lines gave identical results to those obtained in their respective mother tumors.
CONCLUSION: These data might suggest the frequent expression of Fas in the GnRH receptor-bearing tumors, but not in the GnRH receptor-negative tumors. Despite a poorly understood processes of apoptosis at present, there may be at least some similarity in signal transduction pathway utilized by GnRH analogs and Fas ligands.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243207     DOI: 10.1016/s0301-2115(97)02750-4

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.

Authors:  S Aggarwal; M W Ndinguri; R Solipuram; N Wakamatsu; R P Hammer; D Ingram; W Hansel
Journal:  Int J Cancer       Date:  2011-07-20       Impact factor: 7.396

2.  Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.

Authors:  I Pályi; B Vincze; S Lovas; I Mezö; J Pató; A Kálnay; G Turi; D Gaál; R Mihalik; I Péter; I Teplán; R F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

3.  Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.

Authors:  H Das; T Koizumi; T Sugimoto; S Chakraborty; T Ichimura; K Hasegawa; R Nishimura
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

4.  Effect of hyperoside on cervical cancer cells and transcriptome analysis of differentially expressed genes.

Authors:  Weikang Guo; Hui Yu; Lu Zhang; Xiuwei Chen; Yunduo Liu; Yaoxian Wang; Yunyan Zhang
Journal:  Cancer Cell Int       Date:  2019-09-09       Impact factor: 5.722

Review 5.  Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.

Authors:  Carsten Gründker; Günter Emons
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.